Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
New hope for boys with rare muscle disease as experimental drug opens for access
Disease control AVAILABLEThis program provides access to an experimental drug called AOC 1044 for people with Duchenne muscular dystrophy who have specific genetic mutations. The treatment aims to help muscles produce a more functional protein by 'skipping' a problematic section of genetic code. Eligible…
Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Apr 04, 2026 00:35 UTC
-
Breakthrough drug trial offers hope for rare muscle disease
Disease control Recruiting nowThis study is testing an experimental drug called AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 participants will receive either the drug or a placebo via IV infusion every six weeks …
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC